Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alcobra, Arcturus merge in reverse stock swap

Executive Summary

Troubled Israeli biotech Alcobra Ltd. (mostly cognitive disorder therapeutics) has agreed to merge in a reverse stock swap with private US RNA-focused start-up Arcturus Therapeutics Inc. (ATI; rare diseases) to form a new company known as Arcturus Therapeutics Ltd. (ATL), in which Arcturus will have a 60% stake and Alcobra will hold the remainder. Alcobra announced in May it was looking for strategic alternatives (including partnering or M&A opportunities) to create shareholder value.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies